DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government Owned Inventions Available for License: Establishment and Characterization of the A1847 Human Ovarian Carcinoma Line

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this license opportunity should be directed to: Suna Gulay French, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center, Email: *suna.gulay@nih.gov* or Phone: 240–276–7424.

SUPPLEMENTARY INFORMATION: Mutations, such as loss of function, in the BRCA1 gene increase the risk of developing ovarian cancer. In its early stages, ovarian cancer may not cause any definitive symptoms but can rapidly progress within a year to advanced stage. This metastatic growth can occur by shedding cancerous cells into peritoneal fluid, often associated with epithelial ovarian cancer, its most common type. While treatments exist, it is limited by the development of drug resistance that is not succumbed to damage in cell death.

The National Cancer Institute (NCI) researchers derived a metastatic ovarian carcinoma cell line, A1847, from a 50-year-old female. It was established as a continuous tumorigenic cell line and characterized by isozyme phenotype, short tandem repeat (STR) analysis and karyotypically with modal number 68 and 3 marker chromosomes. This cell line may be used to identify therapeutic targets and to screen drug candidates against ovarian cancer.

NCI is seeking parties to nonexclusively license the A1847 human ovarian carcinoma cell line. ''This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.''

NIH Reference Number: E–137–2023–0.

Related Technologies: E–018–2020–0.

Product Type: Research Material/Tool.

Therapeutic Area(s): Oncology.

Publications:

- Standing, D., et al. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer. (PMID *38796478*).
- Sethi, G., et al. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. (PMID *23056589*).
- Godwin, A.K., et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. (PMID *1348364*.)

Potential Commercial Applications:

- Tool to conduct preclinical proof-of-concept studies required for commercial development of anti-cancer agents and targeted therapies in ovarian cancer.
- Research model to investigate epithelial ovarian cancer.
- Research model for mechanistic studies of ovarian cancer and BRCA1-deficient tumors.

Competitive Advantages:

- Well-characterized metastatic ovarian cancer cell line.
- Tumorigenic cell line to generate animal models of metastatic ovarian cancer for commercial and research development.

Collaboration Opportunity: Researchers at the NCI seek licensing for the A1847 ovarian cancer cell line.

Dated: June 10, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026–12070 Filed 6–15–26; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Contracts: Alcohol Registry.

Date: July 1, 2026.

Time: 1:00 p.m. to 3:30 p.m.

Agenda: To review and evaluate contract proposals.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Vanessa S. Boyce, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 4185, MSC 7850, Bethesda, MD 20892, (301) 402–3726, *boycevs@csr.nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Neurovascular, Blood-brain Barrier, and Clearance Pathways.

Date: July 14–15, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Nilkantha Sen, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–9223, *nilkantha.sen@nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Musculoskeletal and Oral Sciences.

Date: July 14, 2026.

Time: 9:00 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Robert Gersch, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 800K, Bethesda, MD 20817, (301) 402–4789, *robert.gersch@nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Preclinical Discovery and Validation of Pharmacotherapeutic and Immunotherapeutic Agents for Non-Cancer Disorders.

Date: July 14, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Andrea Samantha Gobin, Ph.D., Scientific Review Officer,